4.5 Article

Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype

期刊

EXPERIMENTAL AND MOLECULAR PATHOLOGY
卷 92, 期 3, 页码 296-303

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yexmp.2012.03.004

关键词

Colorectal cancer; NHERF1; HIF-1 alpha; TWIST; Hypoxia; Tumor marker

向作者/读者索取更多资源

Over 57% of colorectal cancer (CRC) patients have regional or distant spread of their disease at the time of diagnosis. Despite recent advances, there is a compelling need to better characterize prognostic markers for advanced CRC. The present study investigates protein expression of NHERF1, HIF-1 alpha and TWIST1 and their relationship in distant normal mucosa (DNM), tumor (T) and adjacent normal mucosa (ANM), lymph node metastasis (LNM) and liver metastasis (LM), determining their role as potential markers in advanced stages of human CRC. Overexpression of nuclear NHERF1 was shown in 47% of tumors, which exhibited a significant association with poor histological grade (P=0.0346). Nuclear NHERF1 showed a higher expression in T, LNM and LM than both DNM (P<0.0001) and ANM (P<0.05). Nuclear HIF-1 alpha was significantly higher in T, LNM and LM than DNM and ANM (P<0.05, P<0.001, P<0.0001, respectively). A positive correlation between nuclear NHERF1 and nuclear HIF-1 alpha was found in LNM (r= 0.331, P=0.020), where an extended co-localization of the two proteins was demonstrated. TWIST1 was more expressed in T than DNM and ANM (P<0.0001) and was higher in T than LNM and LM (P<0.0001). Moreover, nuclear NHERF1 was directly correlated to TWIST1 (r= 0.339, P=0.015) in T samples, where a high co-expression of the two proteins was demonstrated both in no longer polarized epithelial cells and in invasive mesenchymal elements adjacent to hypoxic and perinecrotic colonic areas. Overall, nuclear NHERF1 expression was associated with poorer differentiation grade and with higher expression both of HIF-1 alpha in lymphatic metastasis and TWIST1 in invasive front of tumor. Our results support the oncogenic role of NHERF1 and promote nuclear NHERF1 as a potential new biomarker of advanced CRC. (C) 2012 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1

Ana Valencia, Candelaria Vergara, Chloe L. Thio, Nicolas Vince, Venceslas Douillard, Alba Grifoni, Andrea L. Cox, Eric O. Johnson, Alex H. Kral, James J. Goedert, Alessandra Mangia, Valeria Piazzolla, Shruti H. Mehta, Gregory D. Kirk, Arthur Y. Kim, Georg M. Lauer, Raymond T. Chung, Jennifer C. Price, Salim Khakoo, Laurent Alric, Matthew E. Cramp, Sharyne M. Donfield, Brian R. Edlin, Michael P. Busch, Graeme Alexander, Hugo R. Rosen, Edward L. Murphy, Genevieve L. Wojcik, Mary Carrington, Pierre-Antoine Gourraud, Alessandro Sette, David L. Thomas, Priya Duggal, Continue Ignore

Summary: Spontaneous clearance of acute hepatitis C virus (HCV) infection is associated with specific amino acids in HLA-DQ beta 1. Fine-mapping the MHCII region revealed these key amino acids, explaining the allelic and SNP associations with HCV outcomes. This understanding could contribute to the design of vaccines promoting spontaneous clearance of HCV infection.

AMERICAN JOURNAL OF HUMAN GENETICS (2022)

Article Infectious Diseases

Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy

Massimo Andreoni, Nicola Coppola, Antonio Craxi, Stefano Fagiuoli, Ivan Gardini, Alessandra Mangia, Felice Alfonso Nava, Patrizio Pasqualetti

Summary: The study findings suggest that tolerability is considered the most important feature of suitable treatment by hospital clinicians and SerD HCPs, and timely treatment initiation is crucial for the success of the strategy. Drug addiction services patients prefer a complete Meet-Test-Treat pathway within their habitual care center.

BMC INFECTIOUS DISEASES (2022)

Article Gastroenterology & Hepatology

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection

Guiseppe Indolfi, Deirdre Kelly, Gabriella Nebbia, Raffaele Iorio, Anna Mania, Vania Giacomet, Leszek Szenborn, Jiang Shao, Mun Sang Yue, Chia-Hsiang Hsueh, Bandita Parhy, Kathryn Kersey, Alessandra Mangia, Malgorzata Pawlowska, Sanjay Bansal

Summary: Sofosbuvir-velpatasvir-voxilaprevir is a highly effective and well-tolerated pangenotypic regimen for treating chronic HCV infection in adolescents aged 12 to 17 years.

HEPATOLOGY (2022)

Article Virology

Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings

Silvia Rosati, Alexander Wong, Vito Di Marco, Paco Perez-Hernandez, Guilherme Macedo, Christian Brixko, Roberto Ranieri, Francesca Campanale, Annalisa Bascia, Conrado Fernandez-Rodriguez, Victor de Ledinghen, Ivana Maida, Elisabetta Teti, Alessandra Mangia, Kim Vanstraelen, Candido Hernandez, Michael Mertens, Ioanna Ntalla, Heribert Ramroth, Elena Jimenez

Summary: Prison populations are at high risk of HCV infection, but treatment is complicated by social issues. This study analyzed data from Europe and Canada and found that a simple and effective sofosbuvir/velpatasvir treatment achieved high cure rates in prison settings.

FUTURE VIROLOGY (2022)

Letter Gastroenterology & Hepatology

Global multi-stakeholder endorsement of the MAFLD definition

Nahum Mendez-Sanchez, Elisabetta Bugianesi, Robert G. Gish, Frank Lammert, Herbert Tilg, Mindie H. Nguyen, Shiv K. Sarin, Nuria Fabrellas, Shira Zelber-Sagi, Jian-Gao Fan, Gamal Shiha, Giovanni Targher, Ming-Hua Zheng, Wah-Kheong Chan, Shlomo Vinker, Takumi Kawaguchi, Laurent Castera, Yusuf Yilmaz, Marko Korenjak, C. Wendy Spearman, Mehmet Ungan, Melissa Palmer, Mortada El-Shabrawi, Hans-Juergen Gruss, Jean-Francois Dufour, Anil Dhawan, Heiner Wedemeyer, Jacob George, Luca Valenti, Yasser Fouad, Manuel Romero-Gomez, Mohammed Eslam

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Public, Environmental & Occupational Health

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose

Alessandra Mangia, Nicola Serra, Giovanna Cocomazzi, Vincenzo Giambra, Stefano Antinucci, Alberto Maiorana, Francesco Giuliani, Emanuele Montomoli, Paolo Cantaloni, Alessandro Manenti, Valeria Piazzolla

Summary: For naive individuals, low IgG titers are relatively long-lasting. Only a third of naive subjects maintain neutralizing responses. After specific stimulation, a very limited number of naive were unable to produce IFN-gamma. The results of breakthrough infections suggest that simultaneous neutralizing antibody titers < 20, binding antibody levels/ml < 200, and IFN-gamma < 1,000 mIU/ml in subjects older than 58 may identify at-risk groups.

FRONTIERS IN PUBLIC HEALTH (2022)

Article Medicine, General & Internal

Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study

Alessandra Mangia, Annarita Valeria Piazzolla, Maria Maddalena Squillante, Giovanna Cocomazzi, Vanna Maria Valori, Massimiliano Copetti, Paola Parente, Vito Attino, Maria Guido

Summary: Non-alcoholic fatty liver disease (NAFLD) can progress to severe liver fibrosis and cirrhosis. The presence of portal inflammation, high triglycerides levels, advanced fibrosis at baseline, and the duration of follow-up are predictors of disease progression in NAFLD patients.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Health Care Sciences & Services

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)

Stefano Fagiuoli, Pierluigi Toniutto, Nicola Coppola, Domenica Daniela Ancona, Margherita Andretta, Fausto Bartolini, Fulvio Ferrante, Alessandro Lupi, Stefano Palcic, Francesca Vittoria Rizzi, Davide Re, Gema Alvarez Nieto, Candido Hernandez, Francesca Frigerio, Valentina Perrone, Luca Degli Esposti, Alessandra Mangia

Summary: This study investigates the impact of polymedication and aging on the prevalence of drug-drug interactions (DDIs) in HCV patients treated with SOF/VEL or GLE/PIB. The study finds that SOF/VEL patients are older and have more comorbidities and polypharmacy compared to GLE/PIB patients. The simultaneous use of multiple medications can lead to DDIs and increase treatment risks.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2023)

Article Cell Biology

HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy

Alessandra Mangia, Maria Maddalena Squillante, Filippo Fraticelli, Maria Chiara Cavorsi, Giulia Paroni, Lucia Zaffarano, Annarita Valeria Piazzolla

Summary: This study evaluated the impact of baseline viremia on the natural history of HDV infection. The results demonstrated that HDV RNA levels may help identify a subgroup of patients with slower progression of liver disease.
Article Health Care Sciences & Services

Analysis of Patients' Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C : A Real-World Retrospective Italian Analysis

Felice Alfonso Nava, Alessandra Mangia, Marco Riglietta, Lorenzo Somaini, Francesco Giuseppe Foschi, Ernesto Claar, Ivana Maida, Claudio Ucciferri, Francesca Frigerio, Candido Hernandez, Melania Dovizio, Valentina Perrone, Luca Degli Esposti, Massimo Puoti

Summary: This study aimed to analyze the characteristics and clinical features of Hepatitis C virus (HCV) infected people who use drugs (PWUDs) in Italy, with a focus on comorbidity profile, treatment with direct-acting antiviral agents (DAAs), and resource consumption. The study found that HCV-positive individuals were older, had more comorbidities, and had higher rates of drug prescriptions and hospitalizations. Untreated patients with DAAs had more severe comorbidities. These findings provide insights for improving healthcare interventions for HCV-infected PWUDs.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2023)

Meeting Abstract Gastroenterology & Hepatology

CURING HCV WITH DIRECT-ACTING ANTIVIRAL (DAA) TREATMENT: ADHERENCE AND RAPID ONSET OF HCV RNA UNDETECTABILITY AFTER 4 WEEKS OF TREATMENT WITH SOFOSBUVIR/VELPATASVIR

Steven L. Flamm, Graham R. Foster, Marc Bourliere, Stefan Zeuzem, Curtis Cooper, Henry Lik Yuen Chan, Shyam Kottilil, Mark S. Sulkowski, Bruce Kreter, Linda Chen, Renee-Claude Mercier, Kyle P. Hammond, Candido Hernandez, Alessandra Mangia

HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three European countries

Frank Tacke, Juan Turnes, Andreas Hintz, Stefano Fagiuoli, Antoni Sicras-Mainar, Tim Umland, Luca Degli Esposti, Ramon Morillo Verdugo, Antonio Garcia Herola, Mehtap Guendogdu, Marinela Mendez, Gema Alvarez Nieto, Kim Vanstraelen, Candido Hernandez, Alessandra Mangia

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

Alessandra Mangia, Stefano Fagiuoli, Vito Di Marco, Stephen Shafran, Mandana Khalili, Scott Milligan, George Papatheodoridis, Denis Ouzan, Silvia Rosati, Alnoor Ramji, Elisabetta Teti, Montserrat Garcia-Retortillo, Francisco Andres Perez Hernandez, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Elena Jimenez Mutiloa, Luis Enrique Morano Amado, Joss O'Loan, Francesca Campanale, Guilherme Macedo, Michele Milella, Christian Brixko, Maria Buti, Maria Guerra Veloz, Roberto Ranieri, Sergio Borgia, Annalisa Bascia, Conrado Manuel Fernandez Rodriguez, Brian Conway, Victor de Ledinghen, Mary Fenech, Pablo Ryan, Ivana Maida, Alexandra Martins, Stacey Scherbakovsky, Ioanna Ntalla, Candido Hernandez, Kim Vanstraelen, Juan Turnes

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)

Alessandra Mangia, Valeria Piazzolla, Maria Squillante, Giovanna Cocomazzi, Vito Ciciriello, Vincenzo Giambra, Nicola Serra

JOURNAL OF HEPATOLOGY (2022)

暂无数据